Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine - PubMed (original) (raw)
Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine
M C Thomas et al. Hum Gene Ther. 1998.
Abstract
Murine tumor models have demonstrated that whole tumor cell vaccines engineered to secrete certain cytokines in a paracrine fashion elicit systemic immune responses capable of eliminating small amounts of established tumor. In particular, autologous tumors that express the cytokine GM-CSF induce potent systemic immune responses against poorly immunogenic murine tumors. However, phase I clinical trials have demonstrated the technical difficulty of routinely expanding primary autologous human tumor cells to the numbers required for vaccination, making the generalization of autologous vaccines impractical. Dissection of the mechanism by which antitumor immunity is generated has demonstrated that GM-CSF recruits professional antigen-presenting cells that act as intermediates in presenting tumor antigen to and activating effector T cells. Furthermore, the identification of commonly recognized murine and human tumor antigens indicates that many are shared rather than unique. These findings would suggest that allogeneic as well as autologous tumor cells can be used as the vaccinating cells for activating antitumor immunity. A major concern in the application of allogeneic vaccines relates to the potential interference of allogeneic MHC expression at the vaccine site with priming of tumor-specific T cell responses. Here we describe a series of experiments that directly examines the effects of allogeneic MHC molecules on the immune-priming capabilities of a whole cell tumor vaccine engineered to secrete GM-CSF. The results demonstrate that the expression of an allogeneic MHC molecule by a vaccine cell can actually enhance the induction of systemic antitumor immunity. In addition, allogeneic MHC expression has no inhibitory effect on the ability of GM-CSF-transduced vaccines to induce systemic antitumor immunity. These findings support the design of clinical trials for testing this more feasible and generalizable allogeneic whole tumor cell vaccine approach.
Similar articles
- Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K. Li B, et al. Clin Immunol. 2009 Nov;133(2):184-97. doi: 10.1016/j.clim.2009.07.008. Epub 2009 Aug 7. Clin Immunol. 2009. PMID: 19664962 - Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
Chang EY, Chen CH, Ji H, Wang TL, Hung K, Lee BP, Huang AY, Kurman RJ, Pardoll DM, Wu T. Chang EY, et al. Int J Cancer. 2000 Jun 1;86(5):725-30. doi: 10.1002/(sici)1097-0215(20000601)86:5<725::aid-ijc19>3.0.co;2-k. Int J Cancer. 2000. PMID: 10797297 - Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials.
Jaffee EM, Schutte M, Gossett J, Morsberger LA, Adler AJ, Thomas M, Greten TF, Hruban RH, Yeo CJ, Griffin CA. Jaffee EM, et al. Cancer J Sci Am. 1998 May-Jun;4(3):194-203. Cancer J Sci Am. 1998. PMID: 9612602 - Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer.
Simons JW, Sacks N. Simons JW, et al. Urol Oncol. 2006 Sep-Oct;24(5):419-24. doi: 10.1016/j.urolonc.2005.08.021. Urol Oncol. 2006. PMID: 16962494 Review. - GM-CSF-based cancer vaccines.
Dranoff G. Dranoff G. Immunol Rev. 2002 Oct;188:147-54. doi: 10.1034/j.1600-065x.2002.18813.x. Immunol Rev. 2002. PMID: 12445288 Review.
Cited by
- Methods for improving the immunogenicity and efficacy of cancer vaccines.
Pilla L, Ferrone S, Maccalli C. Pilla L, et al. Expert Opin Biol Ther. 2018 Jul;18(7):765-784. doi: 10.1080/14712598.2018.1485649. Epub 2018 Jun 17. Expert Opin Biol Ther. 2018. PMID: 29874943 Free PMC article. Review. - Gene therapy in pancreatic cancer.
Liu SX, Xia ZS, Zhong YQ. Liu SX, et al. World J Gastroenterol. 2014 Oct 7;20(37):13343-68. doi: 10.3748/wjg.v20.i37.13343. World J Gastroenterol. 2014. PMID: 25309069 Free PMC article. Review. - A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer.
Zheng L, Edil BH, Soares KC, El-Shami K, Uram JN, Judkins C, Zhang Z, Onners B, Laheru D, Pardoll D, Jaffee EM, Schulick RD. Zheng L, et al. Ann Surg Oncol. 2014 Nov;21(12):3931-7. doi: 10.1245/s10434-014-3844-x. Epub 2014 Jun 19. Ann Surg Oncol. 2014. PMID: 24943235 Free PMC article. - Peptidases released by necrotic cells control CD8+ T cell cross-priming.
Gamrekelashvili J, Kapanadze T, Han M, Wissing J, Ma C, Jaensch L, Manns MP, Armstrong T, Jaffee E, White AO, Citrin DE, Korangy F, Greten TF. Gamrekelashvili J, et al. J Clin Invest. 2013 Nov;123(11):4755-68. doi: 10.1172/JCI65698. J Clin Invest. 2013. PMID: 24216478 Free PMC article. - Whole cell vaccines--past progress and future strategies.
Keenan BP, Jaffee EM. Keenan BP, et al. Semin Oncol. 2012 Jun;39(3):276-86. doi: 10.1053/j.seminoncol.2012.02.007. Semin Oncol. 2012. PMID: 22595050 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials